NCT06536959 2024-08-05
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
Beijing 302 Hospital
Phase 2 Recruiting
Clinical Trials
3 trialsNCT04712942 2023-08-21
Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat
University of Leipzig
Phase 2 Completed
NCT01460498 2020-03-05
Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)
M.D. Anderson Cancer Center
Phase 1 Completed